FDA Approval of Tisagenlecleucel
- 21 November 2017
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 318 (19), 1861-1862
- https://doi.org/10.1001/jama.2017.15218
Abstract
Approval of the drug tisagenlecleucel (Kymriah; Novartis) by the US Food and Drug Administration (FDA) for the treatment of pediatric and young adult acute lymphoblastic leukemia (ALL) in August 2017 was a landmark in oncology. The science underlying chimeric antigen receptor T cells (CAR-T) heralds a new era of treatment, and the list price of $475 000 for the new drug (delivered as a one-time infusion) definitively shattered oncology drug pricing norms.1This publication has 5 references indexed in Scilit:
- Payer and Policy Maker Steps to Support Value-Based Pricing for DrugsJAMA, 2015
- New Math on Drug Cost-EffectivenessThe New England Journal of Medicine, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Indication-Specific Pricing for Cancer DrugsJAMA, 2014
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsThe New England Journal of Medicine, 1979